107 related articles for article (PubMed ID: 11786730)
1. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
Tampellini M; Berruti A; Gorzegno G; Bitossi R; Bottini A; Durando A; De Matteis A; Farris A; Donadio M; De Fabiani E; Manzin E; Arese P; Sarobba MG; Castiglione F; Moro G; Bonazzi G; Nuzzo F; Massobrio M; Dogliotti L
Tumour Biol; 2001; 22(6):367-73. PubMed ID: 11786730
[TBL] [Abstract][Full Text] [Related]
2. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
Tampellini M; Berruti A; Gerbino A; Buniva T; Torta M; Gorzegno G; Faggiuolo R; Cannone R; Farris A; Destefanis M; Moro G; Deltetto F; Dogliotti L
Br J Cancer; 1997; 75(5):698-702. PubMed ID: 9043027
[TBL] [Abstract][Full Text] [Related]
3. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
[TBL] [Abstract][Full Text] [Related]
6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
7. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CA 15.3 kinetics for metastatic breast cancer.
De La Lande B; Hacene K; Floiras JL; Alatrakchi N; Pichon MF
Int J Biol Markers; 2002; 17(4):231-8. PubMed ID: 12521126
[TBL] [Abstract][Full Text] [Related]
10. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
11. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.
Berruti A; Tampellini M; Torta M; Buniva T; Gorzegno G; Dogliotti L
Eur J Cancer; 1994; 30A(14):2082-4. PubMed ID: 7857707
[TBL] [Abstract][Full Text] [Related]
13. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
Kumpulainen EJ; Keskikuru RJ; Johansson RT
Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
[TBL] [Abstract][Full Text] [Related]
14. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
15. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer.
Al-azawi D; Kelly G; Myers E; McDermott EW; Hill AD; Duffy MJ; Higgins NO
BMC Cancer; 2006 Sep; 6():220. PubMed ID: 16953875
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients.
Wojtacki J; Dziewulska-Bokiniec A; Kowalski DM; Zółtowska A; Ciesielski D; Suszko M
Neoplasma; 1996; 43(4):225-9. PubMed ID: 8931745
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer.
Gonssaud B; Goussot V; Berriolo-Riedinger A; Saïtta-Aribau E; Coutant C; Cochet A; Fumoleau P; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):421-429. PubMed ID: 28751287
[TBL] [Abstract][Full Text] [Related]
18. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
Kruse V; Van de Wiele C; Borms M; Maes A; Pottel H; Sathekge M; Cocquyt V
Nuklearmedizin; 2014 Aug; 53(4):131-8. PubMed ID: 25100557
[TBL] [Abstract][Full Text] [Related]
19. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
